The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation

Nephrol Dial Transplant. 2008 Apr;23(4):1436-41. doi: 10.1093/ndt/gfm762. Epub 2007 Nov 19.

Abstract

Background: Insulin resistance precedes overt diabetes in the general population and hypertriglyceridemia is a reliable marker of the disorder. Thus, patients in the waiting list with hypertriglyceridemia may be at risk for new-onset diabetes after transplantation (NODAT). Objectives. We investigate whether pre-transplant triglyceride (TG) levels are a risk factor for NODAT and whether they exert a combined effect with the type of calcineurin inhibitor (CNI).

Methods: We analysed 314 consecutive non-diabetic recipients [215 cyclosporine A (CsA); 99 tacrolimus (Tacro)] transplanted between 1999 and 2003 with a mean follow-up of 34 months. Outcome was NODAT defined by ADA criteria.

Results: NODAT developed in 81 recipients (25.8%). Multivariate analysis which included a propensity score for factors determining CNI allocation showed that age (OR: 1.06; 95% CI: 1.03-1.09), pre-transplant BMI (OR: 1.1; 95% CI: 1.02-1.17),TG levels (OR: 1.3 per 50 mg/dl increment, 95% CI: 1.07-1.6) and treated acute rejection (OR: 4.8, 95% CI: 3-11), but not the type of CNI, were independent risk factors for NODAT. A significant interaction between pre-transplant TG and type of CNI was observed. Using CsA as the reference, the combination of Tacro plus pre-transplant hypertriglyceridemia (>/=200 mg/dl) showed an OR of 3.26 (1.4-7.8) to develop NODAT, contrasting with an OR of 0.75 (0.34-1.6) in Tacro recipients with pre-transplant TG levels <200 mg/dl.

Conclusion: Pre-transplant hypertriglyceridemia was a risk factor for NODAT only in recipients treated with Tacro; it highlights the importance of pre-transplant insulin resistance in the pathogenesis of NODAT.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / blood
  • Calcineurin / blood
  • Calcineurin Inhibitors*
  • Cyclosporine / therapeutic use
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / etiology*
  • Diabetes Mellitus / prevention & control
  • Female
  • Follow-Up Studies
  • Glucocorticoids / therapeutic use*
  • Graft Rejection / complications
  • Graft Rejection / epidemiology
  • Graft Rejection / prevention & control
  • Humans
  • Hypertriglyceridemia / blood
  • Hypertriglyceridemia / complications*
  • Hypertriglyceridemia / epidemiology
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Insulin Resistance
  • Kidney Transplantation / adverse effects*
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Spain / epidemiology
  • Tacrolimus / therapeutic use
  • Time Factors
  • Triglycerides / blood*

Substances

  • Biomarkers
  • Calcineurin Inhibitors
  • Glucocorticoids
  • Immunosuppressive Agents
  • Triglycerides
  • Cyclosporine
  • Calcineurin
  • Tacrolimus
  • Methylprednisolone